The Federal Trade Commission issued a final order settling claims that Zimmer Holdings' acquisition of Biomet is anticompetitive, according to Imperial Valley News.
Here are five things to know:
1. Zimmer Holdings' acquisition of Biomet is valued at $13.35 billion.
2. When the order was first announced in June 2015, the recently merged company agreed to divest Zimmer's U.S. ZUK unicondylar knee implant rights and assets to London-based Smith & Nephew.
3. Zimmer also agreed to divest Biomet's U.S. Discovery total elbow implant and Cobalt bone cement rights and assets to Vista, California-based DJO Global.
4. The complaint alleged the merger, as it was originally proposed, would eliminate competition between the companies in markets for unicondylar knee implants, total elbow implants and bone cement.
5. The lack of competition, according to the complaint, would increase the likelihood that Zimmer would exercise market power dominance in these markets independently, and would result in decreased levels of quality and service in addition to increased prices.